OR-GUROBI-OPTIMIZATION
2.6.2022 23:28:10 CEST | Business Wire | Press release
Gurobi Optimization, LLC , creator of the world’s fastest mathematical optimization solver, announced the launch of their new educational game that aims to show players the power of optimization. The “Burrito Optimization Game” is a free, web-based app designed for data science and operations research students, as well as anyone who stands to benefit from mathematical optimization. In addition to demonstrating the value of optimization, the game also proves its difficulty, as well as the importance of algorithms and solvers in finding an optimal solution.
Gurobi created the Burrito Optimization Game in collaboration with Dr. Larry Snyder of Lehigh University, who explains that at the time he and Gurobi started work on the project, there were several other projects in the data science community that used the premise of locating a hypothetical new restaurant. The projects scored possible locations based on demographics, demand, and other data science factors.
“As optimizers, we know it can be easy to pick the single best location once you have a score, but if you need to pick five, ten, or fifty locations, especially when there are thousands to choose from, that becomes a very different kind of problem,” says Dr. Snyder. “So we decided to use this as a way to introduce the optimization story, hoping that the idea of first coming up with a score for each location and then putting that into an optimization context would resonate, even for data scientists who hadn’t seen the restaurant examples.”
Gurobi’s game is based on a classic facility location problem and allows players to choose the best locations for a “Guroble” food truck, with the goal of maximizing their total profit. For each level, players are presented with a new story, with added complexity, and a set of data to help them make decisions. The data provided typically includes the cost of each truck, the price of ingredients, and the total sales revenue for each burrito sold, as well as scenarios that will impact decision-making—such as disruptions in the burrito ingredient supply chain, or weather conditions that impact a customer’s willingness to travel.
Players can drag and drop their Guroble trucks around an illustrated map, where they can see how many customers are in each building. The closer the truck is to a building, the more customers from that building will be willing to walk to the truck to buy a burrito. Players can see how their profits adjust when they drag and drop the truck to a different location, highlighting the importance of trade-offs in complex decision-making.
Once a player is satisfied with their placement of the trucks, Gurobi will solve the problem and find the optimal solution within a fraction of a second. Players can then see how far they were from the optimal solution in terms of total profit.
The game also provides tips along the way to further the learning experience once players submit their solution. For example, players might be notified that a certain part of the city is underserved, or they’ll see a hint that their solution has the optimal number of trucks, but in the wrong locations.
In subsequent rounds, the game introduces uncertainties for an added challenge. Players need to build their solutions based off of forecasts rather than actual demand in this game—a concept that’s very familiar for data science students. For example, there might be 25 potential customers forecast in a building, but the actual amount could be off by up to five customers. Error bars indicate how far in either direction the actual demands might be.
“What we’re hoping to convey is that if you were to try optimization by trial and error, it’s not only tedious and time-consuming, but it’s also hard to make good decisions,” explains Dr. Snyder. “We also wanted to make clear that although optimization is hard, it’s a mature scientific field with robust commercial and open-source software that can solve these problems for us.”
“We launched this a little while ago, and the early feedback has been extremely positive,” explained Dr. Edward Rothberg, Chief Executive Officer and Co-founder of Gurobi Optimization. “One common response from optimization professionals is excitement about the prospect of having a simple, entertaining way to show the people they work with the sorts of problems optimization can solve and the power that it brings.”
The Burrito Optimization Game is available on Gurobi’s website , accompanied by a series of resources that highlight intended educational takeaways and explain how instructors can teach the game in a classroom setting or how players can use the game on their own.
About Gurobi Optimization
Gurobi produces the world’s fastest and most powerful mathematical optimization solver—the Gurobi Optimizer—which is used by leading global companies across more than 40 different industries to rapidly solve their complex, real-world problems and make automated decisions that optimize their efficiency and profitability. As the market leader in mathematical optimization software, we aim to deliver not only the best solver, but also the best support—so that companies can fully leverage the power of mathematical optimization (on its own or in combination with other AI techniques such as machine learning) to drive optimal business decisions and outcomes.
Founded in 2008, Gurobi has operations across the Americas, Europe, and Asia and has more than 2,500 customers globally including SAP, Air France, Uber, and the National Football League (NFL). For more information, please visit https://www.gurobi.com/ or call +1 713 871 9341.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220602005982/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
